Skip to main
PYPD
PYPD logo

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd is a clinical-stage biopharmaceutical company advancing its proprietary PLEX technology for targeted drug delivery, focusing on conditions such as surgical site infections with its lead candidate D-PLEX100. Recent developments, including a successful regulatory inspection and a lower-than-expected net loss per share attributed to an increase in share count, bolster investor confidence in the approval prospects for D-PLEX100. Additionally, a strategic collaboration with AdvanzPharma in the EU and the anticipation of a positive outcome from the upcoming pre-NDA meeting highlight the company's potential for significant progress in the biopharmaceutical market.

Bears say

PolyPid faces significant risks surrounding the efficacy of its clinical candidates, as any failure to demonstrate statistically significant results in trials could greatly diminish the value of its product portfolio. Additionally, even successful clinical outcomes do not guarantee regulatory approval from domestic or international authorities, further jeopardizing the company's financial standing. The potential for revenue erosion starting in 2036, stemming from complex patent processes, adds another layer of financial uncertainty for PolyPid’s future performance.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.